LEE, Jae Cheol et al. Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan. Asian Pacific Journal of Cancer Biology, [S. l.], v. 6, n. 2, p. 123–132, 2021. DOI: 10.31557/apjcb.2021.6.2.123-132. Disponível em: https://waocp.com/journal/index.php/apjcb/article/view/663. Acesso em: 10 jun. 2026.